KRAS switch I/II pocket inhibitor
BI-2852
BI-2852 is a potent nanomolar inhibitor of the KRAS switch I/II pocket. It directly targets and inhibits active GTP-bound KRAS. This compound is suitable for in vitro experiments and may be an excellent tool for testing KRAS-related biological hypotheses. pERK modulation and antiproliferative effects were observed in KRASmut cells (NCI-H358) treated with BI-28525,6.
More information
The three human RAS genes, KRAS, NRAS and HRAS encode four different RAS proteins (KRAS-4A, KRAS-4B, NRAS and HRAS) which belong to the protein family of small GTPases. The RAS proteins function as molecular switches between active GTP-bound and inactive GDP-bound conformations. RAS is the most frequently mutated oncogene in human cancers (~27%) with activating mutations mainly in codons 12, 13 and 61. The main mutation in codon 12 causes RAS activation by interfering with GAP binding and GAP-stimulated GTP hydrolysis. KRAS mutations rates are high in pancreatic (~90%), colorectal (~45%) and lung adenocarcinomas (~35%)1,2. KRAS could serve as an excellent drug target for many cancers, but direct inhibition of oncogenic RAS has proven to be challenging. After more than three decades of intense effort, the first anti-RAS therapies have just reached clinical application in the beginning of 20191-6.
Complex of KRAS with BI-2852
BI-2852 binds to KRASG12D with a KD of 740 nM (ITC) and inhibits GTP-KRASG12D binding to effectors like SOS1, CRAF and PI3Kα with an IC50 of 490, 770 and 500 nM. BI-2852 displays an IC50 of 490 nM in a GTP-KRASG12D::SOS1 AlphaScreen (AS) assay leading to low micromolar inhibition (EC50 of 5.8 µM) of pERK (in H358 cell line). BI-2852 displays an IC50 of 490 nM in a GTP-KRASG12D::SOS1 AlphaScreen (AS) assay leading to low micromolar inhibition of pERK (in H358 cell line)5.
| Probe name / negative control | BI-2852 | BI-2853 |
| MW [Da]a | 516.6 | 516.6 |
| ITC (KD) GCP-KRASG12D [µM]b | 0.74 | n.a. |
| ITC (KD) GCP-KRASwt [µM] | 7.5 | n.a. |
| ITC (KD) GDP-KRASG12D [µM] | 2.0 | n.a. |
| ITC (KD) GDP-KRASwt [µM] | 1.1 | n.a. |
| AS (IC50) GTP-KRASG12D::SOS1 [nM] | 490 | 4400 |
| AS (IC50) GTP-KRASG12D::CRAF [nM] | 770 | n.a. |
| AS (IC50) GTP-KRASG12D::PI3Kα [nM] | 500 | n.a. |
| AS (IC50) GDP-KRASG12D::SOS1 [nM] | 260 | 2500 |
| AS (IC50) GTP-KRASwt::SOS1 [nM] | 490 | n.a. |
| EC50 pERK H358 cells (2 h) [µM] | 5.8 | >50 |
| EC50 H358 cells (low serum) [µM] | 6.7 | n.a. |
aFor the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs
bFor assay conditions please refer to reference 5
| Probe name / negative control | BI-2852 | BI-2853 |
| logP @pH 11 | 2.6 | 2.6 |
| Solubility @ pH 6.8 [µg/mL] | 18 | 21 |
| CACO permeability @ pH 7.4 [*10-6 cm/s] | 5.0 | <1.15 |
| CACO efflux ratio | 2.1 | n.a. |
| Microsomal stability (human/mouse/rat) [% QH] | 91 / 93 / 90 | 92 / 95 / 86 |
| Hepatocyte stability (human/mouse/rat) [% QH] | 12 / 21 / 25 | 12 / 69 / 52 |
| Plasma Protein Binding (human/mouse/rat) [%] | 98.8 / 99.5 / 98.5 | 98.7 / 99.1 / 98.6 |
| CYP 3A4 (IC50) [µM] | 4.4 | n.a. |
| CYP 2C8 (IC50) [µM] | 8.4 | n.a. |
| CYP 2C9 (IC50) [µM] | 4.8 | n.a. |
| CYP 2C19 (IC50) [µM] | 11.0 | n.a. |
| CYP 2D6 (IC50) [µM] | 15.0 | n.a. |
No data available, BI-2852 is an in vitro tool compound.
No data available, BI-2852 is an in vitro tool compound
BI-2853 is the less active enantiomer of BI-2852. It shows no effect on cells and is around 10-fold less potent in the AS assays.
BI-2853 which serves as a negative control
| SELECTIVITY DATA AVILABLE | BI-2852 | BI-2853 |
SafetyScreen44™ with kind support of  | Yes | Yes |
| Invitrogen® | No | No |
| DiscoverX® | No | No |
| Dundee | No | No |
Download selectivity data:
BI-2852_selectivityData.xlsx
BI-2853_selectivityData.xlsx
The X-ray crystal structure of target in complex with BI-2852 is available (PDB code: 6GJ8)5.
The in vitro tool compound BI-2852 is a potent nanomolar inhibitor of the KRAS switch I/II pocket and directly inhibits both the active and inactive forms of KRAS.
Drugging an “undruggable” pocket on KRAS
Kessler D., Gmachl M., Mantoulidis A., Martin L. J., Zoephel A., Mayer M., Gollner A., Covini D., Fischer S., Gerstberger T., Gmaschitz T., Goodwin C., Greb P., Häring D., Hela W., Hoffmann J., Karolyi-Oezguer J., Knesl P., Kornigg S., Koegl M., Kousek R., Lamarre L., Moser F., Munico-Martinez S., Peinsipp C., Phan J., Rinnenthal J., Sai J., Salamon C., Scherbantin Y., Schipany K., Schnitzer R., Schrenk A., Sharps B., Siszler G., Sun Q., Waterson A., Wolkerstorfer B., Zeeb M., Pearson M., Fesik S. W. and McConnell D. B.
PNAS 2019, 116 (32), 15823-15829.
When you plan a publication, please use the following acknowledgement:
BI-2852 was kindly provided by Boehringer Ingelheim via its open innovation platform opnMe, available at https://www.opnme.com.